ABB  Vol.4 No.11 A , November 2013
Synergistic effect of Mucuna pruriens and Withania somnifera in a paraquat induced Parkinsonian mouse model
Abstract: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the development of rigidity, resting tremors and postural instability. Recently, the focus of PD’s treatment has shifted towards herbal medicines. Mucuna pruriens (Mp) and Withania somnifera (Ws) are traditional herbal medicines known to have neuro-protective effects due to the L-DOPA present in Mp seed powder and withanoloides present in Ws root extract. Here, the synergistic effect of Mp and Ws in Parkinsonian mice induced by chronic exposure to paraquat was evaluated. Co-treatment with Mp and Ws for 9 weeks, significantly decreased the elevated nitrite levels and lipid peroxidation found in Parkinsonian mice. In behavioural tests, Mp and Ws treated mice showed a significant decrease in the time taken to cross a narrow beam, an increase in the time of stay on drum in rotarod test and an improvement in the hanging time. Furthermore, it was found that the use of Mp and Ws considerably improved the tyrosine hydroxylase expression in the substantianigra region of the brain. The results suggest that Mp and Ws may provide a platform for future drug discoveries and novel treatment strategies for PD.
Cite this paper: Prakash, J. , Yadav, S. , Chouhan, S. , Prakash, S. and Singh, S. (2013) Synergistic effect of Mucuna pruriens and Withania somnifera in a paraquat induced Parkinsonian mouse model. Advances in Bioscience and Biotechnology, 4, 1-9. doi: 10.4236/abb.2013.411A2001.

[1]   Dauer, W. and Przedborski, S. (2003) Parkinson’s disease: Mechanisms and models. Neuron, 39, 889-909.

[2]   Singh, C., Ahmad, I. and Kumar, A. (2007) Pesticides and metals induced Parkinson’s disease: involvement of free radicals and oxidative stress. Cell and Molecular Biology, 30, 19-28.

[3]   Maheswari, T., Vijayraja, D., Kundhavai, N.R., Kalaivani, K., Rajasankar, S., Tamilselvama, K. and Manivasagama, T. (2010) Synergistic neuropreventive effect of Withania somnifera root powder and Mucuna pruriens seed powder in parkinsonic mice model. Journal of Herbal Medicine and Toxicology, 4, 63-69.

[4]   Borah, A. and Mohanakumar, K.P. (2012) L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson’s disease patients. Medical Hypotheses, 79, 271-273.

[5]   Cannon, J.R. and Greenamyre, J.T. (2011) The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicological Sciences, 124, 225-250.

[6]   Gatto, N.M., Cockburn, M., Bronstein, M.A.D. and Ritz, B. (2009) Well-water consumption and Parkinson’s disease in rural California. Environmental Health Perspectives, 117, 1912-1918.

[7]   Semchuk, K.M., Love, E.J. and Lee, R.G. (1992) Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology, 42, 1328-1335.

[8]   Duty, S. and Jenner, P. (2011) Animal models of Parkinson’s disease: A source of novel treatments and clues to the cause of the disease. British Journal of Pharmacology, 164, 1357-1391.

[9]   Singh, S., Singh, K., Patel, S., Patel, D.K., Singh, C., Nath, C. and Singh, M.P. (2008) Nicotine and caffeinemediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridineinduced Parkinson’s disease phenotype in mouse. Brain Research, 1207, 193-206.

[10]   Yadav, S., Dixit, A., Agrawal, S., Singh, A., Srivastava, G., Singh, A.K., Srivastava, P.K., Prakash, O. and Singh, M.P. (2012) Rodent models and contemporary molecular techniques: Notable feats yet incomplete explanations of Parkinson’s disease pathogenesis. Molecular Neurobiology, 46, 495-512.

[11]   Tiwari, M.N., Singh, A.K., Ahmad, I., Upadhyay, G., Singh, D., Patel, D.K., Singh, C., Prakash, O. and Singh, M.P. (2010) Effects of cypermethrin on monoamine transporters, xenobiotic metabolizing enzymes and lipid peroxidation in the rat nigrostriatal system. Free Radical Research, 44, 1416-1424.

[12]   Patel, S., Singh, V., Kumar, A. Gupta, Y.K. and Singh, M.P. (2006) Status of antioxidant defence system and expression of toxicant responsive genes in striatum of maneband paraquat induced Parkinson’s disease phenotype in mouse: mechanism of neurodegeneration. Brain Research, 1081, 9-18.

[13]   Gupta, S.P., Patel, S., Yadav, S., Singh, A.K., Singh, S. and Singh, M.P. (2010) Involvement of nitric oxide in Maneb and paraquat-induced Parkinson’s disease phenotype in mouse: Is there any link with lipid peroxidation. Neurochemical Research, 35, 1206-1213.

[14]   Ngatchic, J.T., Sokeng, S.D., Njintang, N.Y., Maoundombaye, T., Oben, J. and Mbofung, C.M. (2013) Evaluation of some selected blood parameters and histopathology of liver and kidney of rats fed protein-substituted mucuna flour and derived protein rich product. Food and Chemical Toxicology, 57, 46-53.

[15]   Yadav, S.K., Prakash, J., Chouhan, S. and Singh, S.P. (2013) Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model. Neurochemistry International, 62, 1039-1047.

[16]   Suresh, S., Prithiviraj, E., Lakshmi, N.V., Ganesh, M.K., Ganesh, L. and Prakash, S. (2012) Effect of Mucunapruriens (Linn.) on mitochondrial dysfunction and DNA damage in epididymal sperm of streptozotocin induced diabetic rat. Journal of Ethnopharmacology, 145, 32-41.

[17]   Adepoju, G.K.A. and Odubena, O.O. (2009) Effect of Mucuna pruriens on some haematological and biochemical parameters. Journal of Medicinal Plants Research, 3, 73-76.

[18]   Sathiyanarayanan, L. and Arulmozhi, S. (2007) Mucunapruriens L. A comprehensive review. Pharmacognosy Reviews, 1, 157-162.

[19]   Tripathi, Y.B. and Upadhyay, A.K. (2001) Antioxidant property of Mucuna pruriens L. Current Science, 80, 1-11.

[20]   Widodo, N., Kaur, K., Shrestha, B.G., Takagi, Y., Ishii, T., Wadhwa, R. and Kaul S.C. (2007) Selective killing of cancer cells by leaf extract of Ashwagandha: Identification of a tumor-inhibitory factor and the first molecular insights to its effect. Clinical Cancer Research, 13, 2298-2306.

[21]   Kataria, H., Wadhwa, R. and Kaul, S.C. (2013) Withaniasomnifera water extract as a potential candidate for differentiation based therapy of human neuroblastomas. PLoS One, 8, e55316.

[22]   Kulkarni, S.K. and Dhir, A. (2008) Withaniasomnifera: An Indian ginseng. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32, 1093-1105.

[23]   Prakash, J., Yadav, S.K., Chouhan, S. and Singh, S.P. (2013) Neuroprotective role of Withaniasomnifera root extract in maneb-paraquat induced mouse model of Parkinsonism. Neurochemical Research, 38, 972-980.

[24]   Rajasankara, S., Manivasagam, T., Sankar, V., Prakash, S., Muthusamy, R., Krishnamurti, A. and Surendran, S. (2009). Withaniasomnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson’s disease model mouse. Journal of Ethnopharmacology, 125, 369-373.

[25]   Chouhan, S., Prakash, J., Yadav, S.K., Agrawal, N.K. and Singh, S.P. (2013) Effect of bisphenol A on fertility of male mice. Journal of Scientific Research, 57, 77-84.

[26]   Bhattacharya, A., Ghosal, S. and Bhattacharya, S.K. (2001) Anti-oxidant effect of Withaniasomniferaglycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. Journal of Ethnopharmacology, 74, 1-6.

[27]   Kasture, S., Pontis, S., Pinna, A., Schintu, N., Spina, L., Longoni, R., Simola N., Ballero M. and Morelli, M. (2009) Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson’s disease. Neurotoxicity Research, 15, 111-122.

[28]   Mohanasundari, M., Srinivasan, M.S., Sethupathy, S. and Sabesan, M. (2006) Enhanced neuroprotective effect by combination of bromocriptine and Hypericumperforatum extract against MPTP-induced neurotoxicity in mice. Journal of the Neurological Sciences, 249, 140-144.

[29]   Pisa, M. (1998) Regional specialization of motor functions in the rat striatum: implications for the treatment of Parkinsonism. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 12, 217-224.

[30]   Manna, S., Bhattacharyya, D., Mandal, T.K. and Dey, S. (2006) Neuropharmacological effects of deltamethrin in rats. Journal of Veterinary Science, 7, 133-136.

[31]   Ohkawa, H., Ohishi, N. and Yag, K. (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry, 95, 351-358.

[32]   Granger, D.L., Taintor, R.R., Boockvar, K.S. and Hibbs, J.B. (1996) Measurement of nitrate and nitrite in biological samples using nitrate reductase and Greiss reaction. Methods in Enzymology, 268, 142-151.

[33]   Gorbatyuk, O.S., Li, S., Sullivan, L.F., Chen, W., Kondrikova, G., Manfredsson, F.P., Mandel, R.J. and Muzyczka, N. (2008) The phosphorylation state of Ser-129 in human alpha-synuclein determines neurode-generation in a rat model of Parkinson disease. Proceedings of the National Academy of Sciences of the USA, 105, 763-768.

[34]   Singh, S., Singh, K., Patel, D.K., Singh, C., Nath, C., Singh, V.K., Singh, R.K. and Singh, M.P. (2009) The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson’s disease phenotype and nicotine mediated neuroprotection. Rejuvenation Research, 12, 185-197.

[35]   Mochizuki, H., Hayakawa, H., Migit, M., Shibata, M., Tanaka, R., Suzuki, A., Shimo, N.Y., Urabe, T., Yamada, M., Tamayos, K., Shimada, T., Miura, M. and Mizuno, Y. (2001) An AAV-derived apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson’s disease. Proceedings of the National Academy of Sciences of the USA, 98, 10918-10923.

[36]   Martin, P.Y., Bianchi, M., Roger, F., Niksic, L., and Féraille, E. (2002) Arginine vasopressin modulates expression of neuronal NOS in rat renal medulla. American Journal of Physiology, 283, 559-568.

[37]   Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254.

[38]   Mccormack, A.L., Thiruchelvam, M., Manning-Bog, A.B., Thiffault, C., Langston, J.W., Cory-Slechta, D.A., and Di Monte, D.A. (2002) Environmental risk factors and Parkinson’s disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiology of Disease, 10, 119-127.

[39]   Cory-Slechta, D.A., Thiruchelvam, M., Barlow, B.K. and Richfield, E.K. (2005) Developmental pesticide models of the Parkinson disease phenotype. Environmental Health Perspectives, 113, 1263-1270.

[40]   Thiruchelvam, M., Brockel, B.J., Richfield, E.K., Baggs, R.B., and Cory-Slechta, D.A. (2000) Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: Environmental risk factors for Parkinson’s disease? Brain Research, 873, 225-234.

[41]   Kumar, A., Ahmad, I., Shukla, S., Singh, B.K., Patel, D.K., Pandey, H.P, and Singh, C. (2010) Effect of zinc and PQ co-exposure on neurodegeneration: Modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats. Free Radical Research, 44, 950-965.

[42]   Patel, S., Singh, K., Singh, S. and Singh, M.P. (2008) Gene expression profiles of mouse striatum in control and maneb+paraquat-induced Parkinson’s disease phenotype: Validation of differentially expressed energy metabolizing transcripts. Molecular Biotechnology, 40, 59-68.

[43]   Uttara, B., Singh, A.V., Zamboni, P. and Mahajan, R.T. (2009) Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Current Neuropharmacology, 7, 65-74.

[44]   Farooqui, T. and Farooqui, A.A. (2011) Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson’s disease. Parkinson’s Disease, 2011, 1-9.

[45]   Kappus, H. (1986) Overview of enzyme systems involved in bioreduction of drugs and in redox cycling. Biochemical Pharmacology, 35, 1-6.

[46]   Beckman, J.S., Beckman, T.W., Chen, J., Marshall, P.A., and Freeman, B.A. (1990) Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proceedings of the National Academy of Sciences of the USA, 87, 1620-1624.

[47]   Bhatnagar, M., Sharma, D. and Salvi, M. (2009) Neuroprotective effects of Withaniasomniferadunal: A possible mechanism. Neurochemical Research, 34, 1975-1983.

[48]   Yadav, S., Gupta, S.P., Srivastava, G., Srivastava, P.K., and Singh, M.P. (2011) Role of secondary mediators in caffeine-mediated neuroprotection in maneband paraquat-induced Parkinson’s disease phenotype in the mouse. Neurochemical Research, 37, 875-884.

[49]   Dixit, A., Srivastava, G., Verma, D., Mishra, M., Singh, P.K., Prakash, O. and Singh, M.P. (2013) Minocycline, levodopa and MnTMPyP induced chamges in the mitochondrial protein profile of MPTP and maneb and paraquat mice models of Parkinson’s disease. Biochimica et Biophysica Acta, 1832, 1227-1240.

[50]   Somayajulu-Nit, M., Sandhu, J.K., Cohen, J., Sikorska, M., Sridhar, T.S., Matei, A., Borowy-Borowski, H., and Pandey, S. (2009) Paraquatinduces oxidative stress, neuronal loss in substantianigra region and parkinsonism in adult rats: Neuroprotection and amelioration of symptoms by water soluble formulation of coenzyme Q10. BMC Neuroscience, 10, 1-12.

[51]   Ahmad, M., Saleem, S., Ahmad, A.S., Ansari, M.A., Yousuf, S., Hoda, M.N. and Islam, F. (2005) Neuroprotective effects of Withaniasomnifera on 6-hydroxydopamine induced Parkinsonism in rats. Human & Experimental Toxicology, 24, 137-147.

[52]   Dhanasekaran, M., Tharakan, B., and Manyam, B.V. (2008) Antiparkinson drug—Mucuna pruriens shows antioxidant and metal chelating activity. Phytotherapy Research, 22, 6-11.

[53]   Whishaw, I.Q., Li, K., Whishaw, P.A., Gorny, B. and Metz, G.A. (2008) Use of rotorod as a method for the qualitative analysis of walking in rat. Journal of Visualized Experiments, 22, 1030.